human luminal a breast cancer cells  (ATCC)

Journal: Scientific Reports

Article Title: Dual-drug codelivery gelatin-based hydrogel of ARV-471 and Palbociclib enhances synergistic effect in breast cancer treatment

doi: 10.1038/s41598-025-30803-x

Figure Lengend Snippet: Evaluation of HG-Combination in breast cancer cell lines. MCF7 and T47D cell lines were treated with (A) ARV-471, Palbociclib, and their combination and (B) HG-ARV471, HG-Palbociclib, and HG-combination for 72 h, followed by MTT assays ( n = 3). All three replicates for each sample are represented as mean ± standard error of the mean (SEM). * p < 0.05;** p < 0.01; *** p < 0.001. (C) Synergistic studies to evaluate the effect of free combination and HG-Combination. Combination index (CI) for the different drug combinations obtained using CalcuSyn from viability values obtained in an MTT assay. CI values lower than 0.8 indicate synergistic action. * p ≤ 0.05 and ** p ≤ 0.01.

Article Snippet: Luminal breast cancer cell lines MCF7 and T47D, non-tumorigenic keratinocyte cell line HaCaT, and non-tumoral breast epithelial cell line MCF10A were purchased from ATCC (Manassas, VA, USA).

Techniques: MTT Assay

Journal: Scientific Reports

Article Title: Dual-drug codelivery gelatin-based hydrogel of ARV-471 and Palbociclib enhances synergistic effect in breast cancer treatment

doi: 10.1038/s41598-025-30803-x

Figure Lengend Snippet: MCF7 and T47D seeded in Matrigel matrix and treated with the free combination, and HG-Combination at 72 h ( n = 3). The diameter of 3D structures was quantified (µm). All three replicates for each sample are represented as mean ± standard error of the mean (SEM). * p < 0.05;** p < 0.01; *** p < 0.001.

Article Snippet: Luminal breast cancer cell lines MCF7 and T47D, non-tumorigenic keratinocyte cell line HaCaT, and non-tumoral breast epithelial cell line MCF10A were purchased from ATCC (Manassas, VA, USA).

Techniques:

Journal: Scientific Reports

Article Title: Dual-drug codelivery gelatin-based hydrogel of ARV-471 and Palbociclib enhances synergistic effect in breast cancer treatment

doi: 10.1038/s41598-025-30803-x

Figure Lengend Snippet: Effect of HG-Combination on cell cycle and cell death by flow cytometry of MCF7 and T47D cancer cell lines. Empty hydrogel (HG) were used as control. ( A ) Assessment of the influence of treatment (0.5 µM ARV-471 and 5 µM Palbociclib, for 24 h) on cell cycle phases ( n = 3). All three replicates for each sample are represented as mean ± standard error of the mean (SEM). T-test analysis was performed to compare percentage of G0/G1 phase between each treatment and control (non-treated) cells. * p < 0.05; ** p < 0.01; *** p < 0.001. ( B ) Assessment of treatment (0.5 µM ARV-471 and 5 µM Palbociclib, for 72 h) on the cell death of MCF7 and T47D. Cells were classified into different populations: early apoptotic (AV-positive, PI-negative), late apoptotic (AV-positive and PI-positive) and necrotic (annexin V-negative, PI-positive). All three replicates for each sample are represented as mean ± standard error of the mean (SEM). T-test analysis was performed to compare percentage of AV-positive between each treatment and control (non-treated) cells. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Luminal breast cancer cell lines MCF7 and T47D, non-tumorigenic keratinocyte cell line HaCaT, and non-tumoral breast epithelial cell line MCF10A were purchased from ATCC (Manassas, VA, USA).

Techniques: Flow Cytometry, Control